All sponsors

Guangzhou JOYO Pharma Co., Ltd

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-33
RECRUITING3
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO40%

Delay Index: of 5 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Guangzhou JOYO Pharma Co., Ltd on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
JYP0061 15 mg
NCT06158490
P2Enrolling by invitationModerate-to-severe Atopic Dermatitis1202026-02-10 (+12 mo)
JYP0061
NCT06697535
P2RecruitingNeuromyelitis Optica Spectrum Disorders352026-02-28
STAR
NCT06895031
P2RecruitingSolid Tumor; Pancreatic Ductal Adenocarcinoma (PDAC)2102026-03-30
SC1011
NCT06125327
P2/3RecruitingIdiopathic Pulmonary Fibrosis2102026-12-31 (+12 mo)
JYP0066 4% topical cream
NCT07843290
P2Not yet recruitingAtopic Dermatitis (AD)1602027-08-30
Pemetrexed injection
NCT07154368
P3Not yet recruitingNon Small Cell Lung Cancer2072027-10-31
JYP0322 Tablets
NCT07816380
P3Not yet recruitingNSCLC (Advanced Non-small Cell Lung Cancer)2162028-12-30